Providing more complete information

Oct 13, 2025 by orovajewels.com 39 views

Correlation of Major Cardiovascular Clinical Events (KKVM) in Patients with Acute Myocardial Infarction of the ST Segment with Neutrophil Gelatinase Associated-Lipocalin (NGAL) at the Adam Malik Hajj General Hospital Medan

Introduction

Acute myocardial infarction of the ST (STEMI) segment elevation is a leading cause of death worldwide, with a significant impact on public health. The incidence of acute kidney failure in patients with STEMI ranges from 10-25%, highlighting the need for early detection and management of cardiovascular complications. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein released by body cells in response to tissue damage, including kidney damage. This study aims to analyze the correlation between the level of NGAL and the clinical incidence of major cardiovascular (KKVM) events in STEMI patients at the Adam Malik Hajj General Hospital in Medan.

Background

Acute myocardial infarction of the ST segment elevation is a condition where the blood flow to the heart is blocked, causing damage to the heart muscle. The high level of NGAL in STEMI patients can indicate kidney damage associated with heart disease. Increased levels of NGAL are also associated with an increased risk of cardiovascular complications, such as stroke, heart failure, and death. The Ngal Test is a sensitive laboratory test to estimate the level of NGAL in the blood and urine of humans.

The Importance of NGAL in STEMI Patients

NGAL is a protein released by body cells, especially kidney cells, in response to tissue damage. Increased levels of NGAL in the blood or urine can indicate kidney damage, including acute kidney failure. In STEMI patients, the high level of NGAL can indicate kidney damage associated with heart disease. This highlights the need for early detection and management of cardiovascular complications in STEMI patients.

The Role of NGAL in Predicting Major Cardiovascular Clinical Events

This study aims to provide more complete information about the role of NGAL in predicting major cardiovascular clinical events in STEMI patients. The results of this study can help health workers in identifying patients with high risk of experiencing cardiovascular complications and taking appropriate prevention steps. The study is expected to make a significant contribution in increasing understanding and handling cardiovascular diseases in Indonesia.

Implications for Clinical Practice

The results of this study can be beneficial for clinical practice by:

Early detection: Identifying patients with high risk of experiencing cardiovascular complications.
Risk Management: Assist doctors in determining more effective and targeted treatment strategies.
Prevention: Reducing the risk of cardiovascular complications by taking timely precautions.

Methodology

This study will be conducted at the Adam Malik Hajj General Hospital in Medan, Indonesia. The study will involve a retrospective analysis of medical records of STEMI patients who underwent NGAL testing. The study will also involve a prospective analysis of NGAL levels in STEMI patients who are at high risk of experiencing cardiovascular complications.

Expected Outcomes

This study is expected to provide more complete information about the role of NGAL in predicting major cardiovascular clinical events in STEMI patients. The results of this study can help health workers in identifying patients with high risk of experiencing cardiovascular complications and taking appropriate prevention steps. The study is expected to make a significant contribution in increasing understanding and handling cardiovascular diseases in Indonesia.

Conclusion

Acute myocardial infarction of the ST segment elevation is a leading cause of death worldwide, with a significant impact on public health. The high level of NGAL in STEMI patients can indicate kidney damage associated with heart disease. This study aims to analyze the correlation between the level of NGAL and the clinical incidence of major cardiovascular (KKVM) events in STEMI patients at the Adam Malik Hajj General Hospital in Medan. The results of this study can help health workers in identifying patients with high risk of experiencing cardiovascular complications and taking appropriate prevention steps.

Recommendations

Based on the expected outcomes of this study, the following recommendations can be made:

Early detection: Identify patients with high risk of experiencing cardiovascular complications.
Risk Management: Assist doctors in determining more effective and targeted treatment strategies.
Prevention: Reduce the risk of cardiovascular complications by taking timely precautions.

Limitations

This study has several limitations, including:

Small sample size: The study will involve a small sample size of STEMI patients.
Retrospective analysis: The study will involve a retrospective analysis of medical records, which may not be representative of the current situation.
Limited generalizability: The study will be conducted at a single hospital, which may not be representative of other hospitals.

Future Directions

This study can be extended to include a larger sample size and a prospective analysis of NGAL levels in STEMI patients. The study can also be conducted at multiple hospitals to increase the generalizability of the results.
Frequently Asked Questions (FAQs) about Correlation of Major Cardiovascular Clinical Events (KKVM) in Patients with Acute Myocardial Infarction of the ST Segment with Neutrophil Gelatinase Associated-Lipocalin (NGAL)

Q: What is the purpose of this study?

A: The purpose of this study is to analyze the correlation between the level of NGAL and the clinical incidence of major cardiovascular (KKVM) events in STEMI patients at the Adam Malik Hajj General Hospital in Medan.

Q: What is NGAL and how is it related to cardiovascular disease?

A: NGAL is a protein released by body cells, especially kidney cells, in response to tissue damage. Increased levels of NGAL in the blood or urine can indicate kidney damage, including acute kidney failure. In STEMI patients, the high level of NGAL can indicate kidney damage associated with heart disease.

Q: What are the implications of this study for clinical practice?

A: The results of this study can be beneficial for clinical practice by:

Early detection: Identifying patients with high risk of experiencing cardiovascular complications.
Risk Management: Assist doctors in determining more effective and targeted treatment strategies.
Prevention: Reducing the risk of cardiovascular complications by taking timely precautions.

Q: What are the limitations of this study?

A: This study has several limitations, including:

Small sample size: The study will involve a small sample size of STEMI patients.
Retrospective analysis: The study will involve a retrospective analysis of medical records, which may not be representative of the current situation.
Limited generalizability: The study will be conducted at a single hospital, which may not be representative of other hospitals.

Q: What are the expected outcomes of this study?

A: This study is expected to provide more complete information about the role of NGAL in predicting major cardiovascular clinical events in STEMI patients. The results of this study can help health workers in identifying patients with high risk of experiencing cardiovascular complications and taking appropriate prevention steps.

Q: How can this study contribute to the understanding and handling of cardiovascular diseases in Indonesia?

A: This study can make a significant contribution in increasing understanding and handling cardiovascular diseases in Indonesia by:

Providing more complete information: About the role of NGAL in predicting major cardiovascular clinical events in STEMI patients.
Identifying high-risk patients: And taking appropriate prevention steps.
Improving clinical practice: By providing early detection, risk management, and prevention strategies.

Q: What are the potential applications of this study?

A: The potential applications of this study include:

Development of new diagnostic tools: To identify patients with high risk of experiencing cardiovascular complications.
Improvement of treatment strategies: To reduce the risk of cardiovascular complications.
Enhancement of patient outcomes: By providing early detection, risk management, and prevention strategies.

Q: How can this study be extended or replicated?

A: This study can be extended or replicated by:

Increasing the sample size: To include a larger number of STEMI patients.
Conducting a prospective analysis: To include a prospective analysis of NGAL levels in STEMI patients.
Conducting the study at multiple hospitals: To increase the generalizability of the results.

Q: What are the potential risks or challenges associated with this study?

A: The potential risks or challenges associated with this study include:

Limited generalizability: The study will be conducted at a single hospital, which may not be representative of other hospitals.
Small sample size: The study will involve a small sample size of STEMI patients.
Retrospective analysis: The study will involve a retrospective analysis of medical records, which may not be representative of the current situation.